Floatz logo

Derazantinib

Intrahepatic Cholangiocarcinoma

Basilea PharmaceuticaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

39 Active assets in the Intrahepatic Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
Durvalumab
West China Hospital
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai 6th People's Hospital
Phase 2BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B
Atezolizumab
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Derazantinib is also rated in:

combined hepatocellular carcinoma and cholangiocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
urothelial carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
gastric adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →